Hyperkalemia is one of the major reasons for guideline-recommended ACE inhibitors and ARBs are discontinued or fail to reach guideline-recommended dosing for CKD and/or diabetic nephropathy patients ([18, 25]). This evidence concerns the gene ACE and diabetic kidney disease.